<ul>
	<li>Patients with Paget&rsquo;s disease of bone, pediatric and young adult patients with open epiphyses, and patients with prior external beam or implant radiation involving the skeleton: Should not be treated with Teriparatide</li>
	<li>Treatment duration: Use of Teriparatide for more than 2 years during a patient&rsquo;s lifetime is not recommended.</li>
	<li>Patients with bone metastases, history of skeletal malignancies, metabolic bone diseases other than osteoporosis, or hypercalcemic disorders: Should not be treated with Teriparatide</li>
	<li>Laboratory alterations: Teriparatide may increase serum calcium, urinary calcium, and serum uric acid</li>
	<li>Urolithiasis: Use with caution in patients with active or recent urolithiasis because of risk of exacerbation</li>
	<li>Orthostatic hypotension: Transient orthostatic hypotension may occur with initial doses of Teriparatide.</li>
</ul>